VTV THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.96 USD | +4.64% |
|
+12.17% | +134.48% |
| Mar. 14 | VTv Therapeutics Inc. Announces Board Changes | CI |
| Mar. 13 | VTv Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 53.92 | 69.56 | 97.95 | 66.61 | 54.01 | 23.43 |
| Enterprise Value (EV) 1 | 66.83 | 74.65 | 92.75 | 54.03 | 42.58 | 14.44 |
| P/E ratio | -3.81 x | -2.87 x | -10.3 x | -4.65 x | -2.59 x | -1.18 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 4.34 x | 25.2 x | 15.3 x | 16.6 x | 26.8 x | - |
| EV / Revenue | 5.37 x | 27 x | 14.5 x | 13.5 x | 21.1 x | - |
| EV / EBITDA | -3.41 x | -3.58 x | -7.89 x | -2.7 x | -1.9 x | -0.57 x |
| EV / FCF | -4.23 x | -5.08 x | -12.2 x | -5.87 x | -1.62 x | 5.88 x |
| FCF Yield | -23.7% | -19.7% | -8.18% | -17% | -61.8% | 17% |
| Price to Book | -0.65 x | -1.42 x | -1.26 x | -6.84 x | -5.03 x | -0.97 x |
| Nbr of stocks (in thousands) | 509 | 1,023 | 1,317 | 1,674 | 2,037 | 2,037 |
| Reference price 2 | 106.0 | 68.00 | 74.40 | 39.80 | 26.51 | 11.50 |
| Announcement Date | 2/26/19 | 2/21/20 | 2/24/21 | 3/29/22 | 3/6/23 | 3/13/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 12.43 | 2.764 | 6.414 | 4.005 | 2.018 | - |
| EBITDA 1 | -19.61 | -20.85 | -11.76 | -19.97 | -22.45 | -25.41 |
| EBIT 1 | -19.82 | -20.89 | -11.85 | -20.06 | -22.54 | -25.5 |
| Operating Margin | -159.43% | -755.86% | -184.78% | -500.92% | -1,116.95% | - |
| Earnings before Tax (EBT) 1 | -23.64 | -21.84 | -12.8 | -17.62 | -24.87 | -25.97 |
| Net income 1 | -7.911 | -13.04 | -8.499 | -12.99 | -19.16 | -20.25 |
| Net margin | -63.62% | -471.92% | -132.51% | -324.27% | -949.65% | - |
| EPS 2 | -27.79 | -23.65 | -7.212 | -8.554 | -10.24 | -9.712 |
| Free Cash Flow 1 | -15.81 | -14.68 | -7.591 | -9.203 | -26.33 | 2.457 |
| FCF margin | -127.15% | -531.13% | -118.35% | -229.79% | -1,304.7% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/26/19 | 2/21/20 | 2/24/21 | 3/29/22 | 3/6/23 | 3/13/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 3 | 0.009 | 2 | 0.009 | - | 0.009 | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -1.603 | -11.11 | -6.481 | -4.027 | -5.689 | -6.343 | -7.427 |
| Operating Margin | -53.43% | -123,433.33% | -324.05% | -44,744.44% | - | -70,477.78% | - |
| Earnings before Tax (EBT) 1 | - | - | - | -4.091 | -5.468 | -6.09 | -5.774 |
| Net income 1 | - | - | - | -3.151 | -4.261 | -4.745 | -4.499 |
| Net margin | - | - | - | -35,011.11% | - | -52,722.22% | - |
| EPS 2 | - | - | - | -1.600 | -2.000 | -2.400 | -2.400 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 3/29/22 | 5/12/22 | 8/15/22 | 11/10/22 | 3/6/23 | 5/11/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 12.9 | 5.09 | - | - | - | - |
| Net Cash position 1 | - | - | 5.2 | 12.6 | 11.4 | 8.98 |
| Leverage (Debt/EBITDA) | -0.6583 x | -0.2439 x | - | - | - | - |
| Free Cash Flow 1 | -15.8 | -14.7 | -7.59 | -9.2 | -26.3 | 2.46 |
| ROE (net income / shareholders' equity) | 119% | 150% | 507% | -186% | -238% | 409% |
| ROA (Net income/ Total Assets) | -67.9% | -147% | -61.6% | -62.3% | -48% | -72% |
| Assets 1 | 11.64 | 8.903 | 13.8 | 20.85 | 39.93 | 28.11 |
| Book Value Per Share 2 | -163.0 | -47.90 | -59.30 | -5.820 | -5.270 | -11.80 |
| Cash Flow per Share 2 | 3.310 | 1.740 | 4.250 | 8.020 | 5.950 | 4.530 |
| Capex 1 | 0.01 | 0.07 | - | - | 0.02 | - |
| Capex / Sales | 0.04% | 2.53% | - | - | 1.04% | - |
| Announcement Date | 2/26/19 | 2/21/20 | 2/24/21 | 3/29/22 | 3/6/23 | 3/13/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +134.48% | 65.6M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- VTVT Stock
- Financials vTv Therapeutics Inc.
